Prostaglandin E receptor family (EP1-4)

The Prostaglandin E receptor family (PTGER1-4) consists of four distinct G protein-coupled receptors—EP1, EP2, EP3, and EP4—that mediate the biological effects of Prostaglandin E2 (PGE2) [1, 4]. These receptors are widely distributed and couple to different intracellular signaling pathways: EP1 primarily increases intracellular calcium via Gq; EP2 and EP4 stimulate adenylate cyclase to increase cAMP via Gs; and EP3 typically inhibits adenylate cyclase to decrease cAMP via Gi [2, 11]. This signaling diversity allows the family to regulate a broad range of physiological processes, including inflammation, pain perception, smooth muscle tone, and renal function [1, 5]. In disease states, dysregulation of EP receptor signaling is heavily implicated in chronic inflammation, various cancers (where it promotes tumor cell survival and angiogenesis), and cardiovascular disorders [2, 3, 10]. Consequently, the EP receptors are significant therapeutic targets, with various agonists and antagonists in development or clinical use for treating conditions such as pain, glaucoma, labor induction, and inflammatory diseases [2, 8]. Drugs like misoprostol and dinoprostone are commonly used to target these pathways for gastric protection and cervical ripening, respectively [6].

Other names

PTGER1PTGER2PTGER3PTGER4EP1EP2EP3EP4Prostanoid EP receptorsProstaglandin E2 receptorsProstaglandin E receptor 1Prostaglandin E receptor 2Prostaglandin E receptor 3Prostaglandin E receptor 4

Agonism or antagonism of specific EP receptor subtypes (EP1, EP2, EP3, EP4) to modulate intracellular secondary messengers, specifically cyclic AMP (cAMP) and calcium ions (Ca2+), thereby regulating downstream signaling cascades such as PKA, PKC, and MAPK pathways.